Keytruda (pembrolizumab) v indikácii ca endometria podľa klinického skúšania KN868

Organisation: Merck Sharp & Dohme, s.r.o.

Created at: 26.03.2025

Processed at: 02.04.2026

Question

Please include Keytruda (pembrolizumab) in the indication ca endometrium in case of a final decision of the Ministry of Health of the Slovak Republic in the DRG as an attributable item.

NA-Keytruda (pembrolizumab) in the indication KN868 ca endometrial

patients with endometrial cancer requiring first-line treatment for primary advanced or recurrent cancer during hospitalisation according to the above IO

Answer

The indication restrictions (IOs) in the DRG system are aligned with the IOs that are listed in the categorisation list of medicines. As the SK-DRG system is updated only once a year and new indications enter the categorisation list all year round, in order to avoid misalignment of the two systems, the reporting of indication restrictions has been transferred to marker reporting, which makes the DRG system more flexible and as soon as a medicine is categorised under a new indication, it can also be reported under the DRG system.